What is TAE Life Sciences?
TAE Life Sciences is at the forefront of developing advanced cancer therapies, specializing in Boron Neutron Capture Therapy (BNCT). This biologically targeted radiotherapy approach is designed to offer effective treatment for difficult-to-treat malignancies while minimizing collateral damage to healthy tissues. The company's proprietary Alphabeam Neutron System is key to its precision targeting capabilities, aiming to revolutionize cancer care with therapies potentially requiring only one to two treatment sessions.
How much funding has TAE Life Sciences raised?
TAE Life Sciences has raised a total of $70M across 2 funding rounds:
Series A
$40M
Series B
$30M
Series A (2018): $40M with participation from ARTIS Ventures
Series B (2020): $30M led by ARTIS Ventures
Key Investors in TAE Life Sciences
ARTIS Ventures
Artis Ventures is a venture capital fund focused on Tech Bio+Health, investing in innovative data-driven life sciences companies. They aim to enhance human health and wellness through scalable medical technologies leveraging AI and engineering for personalized therapeutics and efficient drug discovery.
What's next for TAE Life Sciences?
With the recent major strategic investment, TAE Life Sciences is poised for significant expansion and further development of its BNCT technology. The substantial capital infusion, indicated by the $70M total funding, suggests the company is moving beyond its early development stages and is likely scaling its operations, potentially for broader clinical trials, regulatory approvals, and market penetration. This strategic financing will enable TAE Life Sciences to accelerate its mission of transforming cancer treatment paradigms and bringing its innovative solutions to a wider patient population.
See full TAE Life Sciences company page
